Medical diagnostics company Rhythm Biosciences (ASX: RHY) has undertaken a comprehensive strategic review following major shareholder discontent and a subsequent…
Rhythm Biosciences (ASX: RHY) is a step closer to commercialising their bowel cancer detection test, having submitted documents to the…
Colorectal cancer is the third most commonly occurring cancer in men, and the second in women. Yet every year 130…
We recently had a one-on-one meeting with Mr. Glenn Gilbert, CEO of Rhythm Biosciences (ASX: RHY). As we do not…
Aussie medtech company Rhythm Biosciences (ASX: RHY) is set to improve the screening process of colorectal cancer with manufacturing of…